Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 18 December 2008. doi:10.1136/hrt.2008.152223
Heart 2009;95:283-289
Copyright © 2009 BMJ Publishing Group Ltd & British Cardiovascular Society

ORIGINAL ARTICLES

Heart failure and cardiomyopathy

Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation

K Yamahara1, K D Min2, H Tomoike2, K Kangawa3, S Kitamura4, N Nagaya1

1 Department of Regenerative Medicine & Tissue Engineering, National Cardiovascular Center Research Institute, Osaka, Japan
2 Department of Cardiovascular Medicine, National Cardiovascular Center, Osaka, Japan
3 Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka, Japan
4 Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan

Dr K Yamahara, Fujishirodai 5-7-1, Suita, Osaka 565-8565, Japan; yamahara{at}ri.ncvc.go.jp

ABSTRACT

Objective: Recently, a clinical trial was initiated to evaluate the efficacy of transendocardial transplantation of autologous bone marrow-derived mesenchymal stem cells (MSC) for the treatment of heart failure (HF). Because some HF patient-derived sera did not induce proliferation of autologous MSC, the present study aimed to elucidate humoral factors in sera that attenuate MSC activation and to investigate the role of these humoral factors in the pathogenesis of HF.

Methods and results: Inhibitory effects present in serum were analysed by culturing human MSC with sera from 10 HF patients (FS <25%, BNP >100 pg/ml) and four healthy control subjects. Among the patients, two sera from HF patients showed significant inhibitory activity on MSC proliferation. Protein array and ELISA analysis revealed that these sera contained high levels of angiostatin as well as the active form of matrix metalloproteinase (MMP)-9, which generates angiostatin. Angiostatin significantly inhibited the proliferation and migration of cultured human MSC and increased their apoptosis in a dose-dependent manner. In a rat HF model, serum levels of angiostatin and MMPs increased, but treatment with an MMP inhibitor suppressed these increases.

Conclusions: The results suggest that angiostatin, which can attenuate the activity of MSC, might play a role in the progression of HF.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Angiostatin: drying out the roots in cardiac muscle
Konrad F Frank and Jochen Müller-Ehmsen
Heart 2009 95: 269-270. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Kitahori, K., He, H., Kawata, M., Cowan, D. B., Friehs, I., del Nido, P. J., McGowan, F. X. Jr (2009). Development of Left Ventricular Diastolic Dysfunction With Preservation of Ejection Fraction During Progression of Infant Right Ventricular Hypertrophy. Circ Heart Fail 2: 599-607 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.